TYSABRI (natalizumab)
Topics
[2] (Abst.) Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy
[3] Tysabri biosimilar for relapsing MS under FDA review
[4] (Abst.) Developing a model of care for home infusions of Tysabri...
[5] Biogen Seeks preliminary injunction in case against Sandoz
[6] (AAN) PML risk cut by extending Tysabri dosing interval
[7] (ACTRIMS) PML incidence rates in US patients treated w/natalizumab
[8] (Abst.) MS disease activity and disability after discontinuing Tysabri for pregnancy
[9] JCV mutations may predict Tysabri-related PML
Navigation
[0] Up one level
[#] Next page
Go to full version